Literature DB >> 33127576

Comparative analysis of genome-wide DNA methylation identifies patterns that associate with conserved transcriptional programs in osteosarcoma.

Lauren J Mills1, Milcah C Scott2, Pankti Shah3, Anne R Cunanan3, Archana Deshpande4, Benjamin Auch4, Bridget Curtin5, Kenneth B Beckman4, Logan G Spector6, Aaron L Sarver7, Subbaya Subramanian8, Todd A Richmond3, Jaime F Modiano9.   

Abstract

Osteosarcoma is an aggressive tumor of the bone that primarily affects young adults and adolescents. Osteosarcoma is characterized by genomic chaos and heterogeneity. While inactivation of tumor protein p53 (TP53) is nearly universal other high frequency mutations or structural variations have not been identified. Despite this genomic heterogeneity, key conserved transcriptional programs associated with survival have been identified across human, canine and induced murine osteosarcoma. The epigenomic landscape, including DNA methylation, plays a key role in establishing transcriptional programs in all cell types. The role of epigenetic dysregulation has been studied in a variety of cancers but has yet to be explored at scale in osteosarcoma. Here we examined genome-wide DNA methylation patterns in 24 human and 44 canine osteosarcoma samples identifying groups of highly correlated DNA methylation marks in human and canine osteosarcoma samples. We also link specific DNA methylation patterns to key transcriptional programs in both human and canine osteosarcoma. Building on previous work, we built a DNA methylation-based measure for the presence and abundance of various immune cell types in osteosarcoma. Finally, we determined that the underlying state of the tumor, and not changes in cell composition, were the main driver of differences in DNA methylation across the human and canine samples. SIGNIFICANCE: Genome wide comparison of DNA methylation patterns in osteosarcoma across two species lays the ground work for the exploration of DNA methylation programs that help establish conserved transcriptional programs in the context of varied mutational landscapes.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Comparative oncology; DNA methylation; EPIGENETIC; Osteosarcoma

Mesh:

Year:  2020        PMID: 33127576      PMCID: PMC8076342          DOI: 10.1016/j.bone.2020.115716

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  58 in total

1.  Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group.

Authors:  David Ebb; Paul Meyers; Holcombe Grier; Mark Bernstein; Richard Gorlick; Steven E Lipshultz; Mark Krailo; Meenakshi Devidas; Donald A Barkauskas; Gene P Siegal; William Shay Ferguson; George Douglas Letson; Karen Marcus; Allen Goorin; Peter Beardsley; Neyssa Marina
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

Review 2.  From genomics to metabolomics: emerging metastatic biomarkers in osteosarcoma.

Authors:  Dylan C Dean; Shen Shen; Francis J Hornicek; Zhenfeng Duan
Journal:  Cancer Metastasis Rev       Date:  2018-12       Impact factor: 9.264

3.  Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach.

Authors:  Milcah C Scott; Aaron L Sarver; Katherine J Gavin; Venugopal Thayanithy; David M Getzy; Robert A Newman; Gary R Cutter; Kerstin Lindblad-Toh; William C Kisseberth; Lawrence E Hunter; Subbaya Subramanian; Matthew Breen; Jaime F Modiano
Journal:  Bone       Date:  2011-05-15       Impact factor: 4.398

4.  Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics.

Authors:  Gaëlle Pérot; Frédéric Chibon; Audrey Montero; Pauline Lagarde; Hugues de Thé; Philippe Terrier; Louis Guillou; Dominique Ranchère; Jean-Michel Coindre; Alain Aurias
Journal:  Am J Pathol       Date:  2010-10       Impact factor: 4.307

5.  Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice.

Authors:  Sam D Molyneux; Marco A Di Grappa; Alexander G Beristain; Trevor D McKee; Daniel H Wai; Jana Paderova; Meenakshi Kashyap; Pingzhao Hu; Tamara Maiuri; Swami R Narala; Vuk Stambolic; Jeremy Squire; Josef Penninger; Otto Sanchez; Timothy J Triche; Geoffrey A Wood; Lawrence S Kirschner; Rama Khokha
Journal:  J Clin Invest       Date:  2010-08-09       Impact factor: 14.808

6.  C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression.

Authors:  G Gamberi; M S Benassi; T Bohling; P Ragazzini; L Molendini; M R Sollazzo; F Pompetti; M Merli; G Magagnoli; A Balladelli; P Picci
Journal:  Oncology       Date:  1998 Nov-Dec       Impact factor: 2.935

7.  Impaired bone development and increased mesenchymal progenitor cells in calvaria of RB1-/- mice.

Authors:  Gabriel M Gutierrez; Elizabeth Kong; Yves Sabbagh; Nelson E Brown; Jong-Seo Lee; Marie B Demay; David M Thomas; Philip W Hinds
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-19       Impact factor: 11.205

8.  Identification of Differentially Expressed MicroRNAs in Osteosarcoma.

Authors:  Rishi R Lulla; Fabricio F Costa; Jared M Bischof; Pauline M Chou; Maria de F Bonaldo; Elio F Vanin; Marcelo B Soares
Journal:  Sarcoma       Date:  2011-07-18

Review 9.  Risk Factors for Development of Canine and Human Osteosarcoma: A Comparative Review.

Authors:  Kelly M Makielski; Lauren J Mills; Aaron L Sarver; Michael S Henson; Logan G Spector; Shruthi Naik; Jaime F Modiano
Journal:  Vet Sci       Date:  2019-05-25

10.  WGCNA: an R package for weighted correlation network analysis.

Authors:  Peter Langfelder; Steve Horvath
Journal:  BMC Bioinformatics       Date:  2008-12-29       Impact factor: 3.169

View more
  2 in total

1.  miR-486-5p expression is regulated by DNA methylation in osteosarcoma.

Authors:  Heidi M Namløs; Magne Skårn; Deeqa Ahmed; Iwona Grad; Kim Andresen; Stine H Kresse; Else Munthe; Massimo Serra; Katia Scotlandi; Antonio Llombart-Bosch; Ola Myklebost; Guro E Lind; Leonardo A Meza-Zepeda
Journal:  BMC Genomics       Date:  2022-02-17       Impact factor: 3.969

2.  Sorafenib and Doxorubicin Show Synergistic Effects in Human and Canine Osteosarcoma Cell Lines.

Authors:  Ya-Ting Yang; Vilma Yuzbasiyan-Gurkan
Journal:  Int J Mol Sci       Date:  2022-08-19       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.